[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:b-cell-lymphoma-unclassifiable":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"B-cell Lymphoma, Unclassifiable",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06563505","A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed\u002FRefractory Marginal Zone Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-07-30T01:46:14.469172Z",[],[]]